Detalhe da pesquisa
1.
Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
Eur J Immunol
; 51(3): 544-556, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33450785
2.
Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
Blood
; 127(26): 3387-97, 2016 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27121473
3.
Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth.
Clin Cancer Res
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38772416
4.
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma.
Nat Commun
; 14(1): 3378, 2023 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37291228
5.
CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models.
Cancers (Basel)
; 14(14)2022 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35884422
6.
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
Cancers (Basel)
; 12(4)2020 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32331483
7.
Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs).
Sci Rep
; 10(1): 8869, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32483228
8.
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
Front Immunol
; 11: 622442, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33569063
9.
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Front Immunol
; 10: 453, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30941125
10.
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).
Oncoimmunology
; 7(3): e1395127, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29375935
11.
Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
Clin Cancer Res
; 24(20): 5098-5111, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30068707
12.
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
Oncotarget
; 8(44): 78174-78192, 2017 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29100459